OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance

OrthoPediatrics posts record Q3 revenue and narrows net loss, raising 2026 guidance.

What the company is saying

OrthoPediatrics Corp. is highlighting a strong third quarter, with record total revenue of $72.7 million, up 19% from $61.2 million a year earlier. The company emphasizes broad-based growth: domestic revenue rose 19% to $57.9 million, international revenue climbed 18% to $14.8 million, Trauma & Deformity revenue increased 19% to $52.6 million, and Scoliosis revenue advanced 18% to $19.2 million. Management, led by President & CEO David Bailey, frames the quarter as a continuation of momentum, citing market share gains, improved profitability, and positive free cash flow of $1.6 million (a $5.0 million improvement over last year). The announcement stresses the impact of new product launches, including the 3P Pediatric Plating Platform Hip System and PediHip Rigid Brace, and points to an 'innovation super cycle' as a future growth driver. The company raises full-year 2026 revenue guidance to $270.0–$273.0 million (14–16% growth) and reiterates targets for $25.0 million adjusted EBITDA and breakeven free cash flow. The tone is confident, with management attributing improvements to increased procedure volumes, product launches, and disciplined cost control.

What the data suggests

The disclosed figures show OrthoPediatrics is delivering accelerating top-line growth, with Q3 2026 revenue up 19% year-over-year and gross profit up 19% to $54.0 million, while maintaining a stable gross margin of 74%. Adjusted EBITDA reached a record $6.9 million, up from $6.2 million, and free cash flow turned positive at $1.6 million versus a $3.4 million outflow last year. Net loss narrowed to $5.9 million from $11.8 million, and loss per share improved to $0.25 from $0.50. Operating expenses rose 6% to $58.2 million, driven by higher sales commissions and personnel for expansion, but this was outpaced by revenue growth. Cash and equivalents declined to $44.9 million from $62.9 million at year-end, reflecting ongoing investment but improved operational cash generation. The company increased full-year revenue guidance to $270.0–$273.0 million and expects adjusted EBITDA of $25.0 million and breakeven free cash flow, signaling confidence in sustained performance. Management attributes growth to higher procedure volumes, new product launches, and improved working capital metrics.

Analysis

The announcement's tone is positive but proportionate to the actual results disclosed. The company provides detailed, realised financial and operational metrics for the third quarter of 2026, including record revenue, improved adjusted EBITDA, and a significant improvement in free cash flow. While management reiterates confidence in future performance and raises full-year guidance, these forward-looking statements are incremental and grounded in recent realised results. The majority of key claims are realised and substantiated by numerical data, with only a minority being forward-looking projections for the remainder of 2026. There is no evidence of exaggerated narrative or overstatement; the language is optimistic but supported by the data. Capital outlays for set deployment and clinic expansion are moderate and matched by improving cash flow and profitability, with no indication of large, long-dated, or uncertain returns.

Risk flags

• ●Despite strong revenue growth, the company remains unprofitable, posting a net loss of $5.9 million in Q3 2026. Continued net losses may limit financial flexibility if growth slows or costs rise unexpectedly.
• ●Cash and equivalents declined from $62.9 million at year-end 2025 to $44.9 million at September 30, 2026, reflecting ongoing investment and the need to sustain positive free cash flow. If operational improvements stall, liquidity could become a concern.
• ●Operating expenses increased 6% year-over-year, with sales and marketing up 24% and general and administrative up 10%, largely due to expansion and acquisitions. If revenue growth slows, elevated cost structure could pressure margins.
• ●Intangible asset impairment of $0.6 million signals some assets (ApiFix and MedTech trademarks) are underperforming expectations, raising questions about the long-term value of certain acquisitions or product lines.

Bottom line

OrthoPediatrics is executing on its growth strategy, delivering record Q3 revenue, improved adjusted EBITDA, and a swing to positive free cash flow, while narrowing its net loss. The company is benefiting from strong demand in core segments and successful new product launches, with management raising full-year guidance and projecting breakeven free cash flow in 2026. While profitability remains elusive, the trajectory is positive and operational leverage is improving. Risks remain around sustained cost discipline, the need to maintain revenue momentum, and the impact of asset impairments. Investors should focus on the company's ability to sustain positive free cash flow and move toward net profitability as the next key milestone. The most important takeaway is that OrthoPediatrics is showing tangible progress toward financial self-sufficiency, but must continue to execute to fully realize its potential.

Announcement summary

(NASDAQ:KIDS) OrthoPediatrics Corp. reported financial results for the third quarter ended September 30, 2026. The company helped nearly 42,000 children in the third quarter of 2026. Total revenue reached a new record high of $72.7 million for the third quarter of 2026, up 19% from $61.2 million in the third quarter of 2025. Domestic revenue increased 19% to $57.9 million, while international revenue increased 18% to $14.8 million. Trauma & Deformity revenue grew 19% to $52.6 million, and Scoliosis revenue grew 18% to $19.2 million. Sports Medicine/Other revenue was $0.9 million, a 2% increase from $0.8 million in the prior year period. The company achieved record adjusted EBITDA of $6.9 million, compared to $6.2 million in the third quarter of 2025. Free cash flow generated in the third quarter of 2026 was $1.6 million, a $5.0 million improvement compared to $3.4 million of usage in the prior year period. Gross profit for the third quarter of 2026 was $54.0 million, a 19% increase from $45.3 million, with a gross profit margin of 74%. Total operating expenses were $58.2 million, up 6% from $54.7 million, driven mainly by increased sales commission expense and additional personnel for clinic expansions and acquisitions. Sales and marketing expenses increased $4.4 million, or 24%, to $23.1 million. Research and development expenses increased $0.1 million, or 6%, to $2.5 million. General and administrative expenses increased $2.9 million, or 10%, to $32.0 million. An intangible asset impairment of $0.6 million was recorded due to the fair value of ApiFix and MedTech trademark assets being below carrying value. Total other expense was $1.8 million, compared to $2.5 million in the prior year, with the change primarily driven by a $0.8 million non-cash fair value adjustment of contingent consideration, additional interest expense, and changes in foreign exchange gains and losses. Net loss for the third quarter of 2026 was $5.9 million, compared to $11.8 million in the prior year. Net loss per share was $0.25 per basic and diluted share, compared to $0.50 per share in the prior year. Weighted average basic and diluted shares outstanding for the quarter were 24,153,621. As of September 30, 2026, cash, cash equivalents, short-term investments, and restricted cash totaled $44.9 million, compared to $62.9 million as of December 31, 2025. The company announced the full market release of the 3P Pediatric Plating Platform Hip System and the PediHip Rigid Brace, as well as FDA clearance and limited launches of several new products. Full year 2026 revenue guidance was increased to $270.0 million to $273.0 million from the prior range of $265.0 million to $269.0 million, representing growth of 14% to 16% over 2025 revenue. The company reiterated expectations for annual set deployment of approximately $10.0 million, adjusted EBITDA of approximately $25.0 million, and breakeven free cash flow in 2026. OrthoPediatrics will host a conference call on October 27, 2026, at 4:30 p.m. ET to discuss the results. David Bailey, President & CEO, stated that the company continued to gain share in Trauma and Deformity and Scoliosis globally, improved profitability, and generated positive free cash flow. He emphasized the importance of the company's innovation pipeline and focus on growing the business, improving operating performance, and achieving breakeven or better free cash flow on an annual basis in 2026 and beyond.

Disagree with this article?